AR038924A1 - Utilizacion del acido 6-[3-(1-adamantil)-4-metoxifenil)-2-naftoico para el tratamiento de desordenes dermatologicos - Google Patents

Utilizacion del acido 6-[3-(1-adamantil)-4-metoxifenil)-2-naftoico para el tratamiento de desordenes dermatologicos

Info

Publication number
AR038924A1
AR038924A1 ARP030100823A ARP030100823A AR038924A1 AR 038924 A1 AR038924 A1 AR 038924A1 AR P030100823 A ARP030100823 A AR P030100823A AR P030100823 A ARP030100823 A AR P030100823A AR 038924 A1 AR038924 A1 AR 038924A1
Authority
AR
Argentina
Prior art keywords
adapalene
treatment
inflammatory
pharmaceutical composition
weight
Prior art date
Application number
ARP030100823A
Other languages
English (en)
Original Assignee
Galderma Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Res & Dev filed Critical Galderma Res & Dev
Publication of AR038924A1 publication Critical patent/AR038924A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

Utilización del ácido 6-[3-(1-adamantil)-4-metoxifenil]-2-naftanoico (adapaleno) o de sus sales para la fabricación de una composición farmacéutica destinada al tratamiento de las afecciones dermatológicas de componente inflamatorio o proliferativo que comprende 0,3% de peso de adapaleno con respecto al peso total de la composición. Reivindicación 1: Utilización del ácido 6-[3-(1-adamantil)-4-metoxifenil]-2-naftanoico (adapaleno) o de sus sales para la fabricación de una composición farmacéutica destinada al tratamiento de las afecciones dermatológicas de componente inflamatorio o proliferativo elegidas entre los acnés vulgares, comedonianos, polimorfos, los acnés noduloquísticos, conglobata, los acnés secundarios tales como el acné solar, medicamentoso o profesional, las formas extendidas y/o severas de psoriasis, las ictiosis y los estados ictiosiformes, la enfermedad de Darier, las queratodermias palmoplantares y la queratosis pilar, y las pigmentaciones postinflamatorias, caracterizada porque la composición farmacéutica comprende 0,3% de peso de adapaleno con respecto al peso total de la composición. Reivindicación 7: Composición farmacéutica que comprende, en un medio fisiológicamente aceptable, ácido 6-[3-(1-adamantil)-4-metoxifenil]-2-naftanoico (adapaleno) o de sus sales destinada al tratamiento de las afecciones dermatológicas de componente inflamatorio proliferativo caracterizada porque comprende 0,3% de peso de adapaleno con respecto al peso total de la composición.
ARP030100823A 2002-03-12 2003-03-11 Utilizacion del acido 6-[3-(1-adamantil)-4-metoxifenil)-2-naftoico para el tratamiento de desordenes dermatologicos AR038924A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0203070A FR2837101B1 (fr) 2002-03-12 2002-03-12 Utilisation de l'acide 6-[1-adamantyl)-4-methoxyphenyl]-2- naphthoique pour le traitement de desordres dermatologiques

Publications (1)

Publication Number Publication Date
AR038924A1 true AR038924A1 (es) 2005-02-02

Family

ID=27772059

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030100823A AR038924A1 (es) 2002-03-12 2003-03-11 Utilizacion del acido 6-[3-(1-adamantil)-4-metoxifenil)-2-naftoico para el tratamiento de desordenes dermatologicos

Country Status (4)

Country Link
KR (1) KR101007161B1 (es)
AR (1) AR038924A1 (es)
FR (1) FR2837101B1 (es)
ZA (1) ZA200405853B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100798853B1 (ko) * 2005-02-15 2008-01-28 (주)한국스티펠 레티노이드를 유효성분으로 하는 백반증 예방 및 치료용 약학적 조성물
FR2901701B1 (fr) * 2006-05-31 2010-10-29 Galderma Res & Dev Compostions comprenant au moins un derive de l'acide naphtoique et au moins un agent filmogene, leurs procedes de preparation, et leurs utilisations
FR2903603B1 (fr) 2006-07-13 2009-03-20 Galderma Res & Dev S N C Snc Combinaison d'adapalene et de peroxyde de benzole dans le traitement de l'acne
EP2097075A1 (fr) * 2006-11-20 2009-09-09 Galderma Research & Development, S.N.C. Utilisation d'adapalène pour moduler l'expression de cd1d ou il-10.
EP2097076A1 (fr) * 2006-11-20 2009-09-09 Galderma Research & Development, S.N.C. Utilisation d'adapalène pour moduler l'expression de l'il-1ra.
JP2013518920A (ja) 2010-02-09 2013-05-23 ガルデルマ・リサーチ・アンド・デヴェロップメント 非白人系人種における炎症後色素沈着の減少と共にざ瘡の処置を目的とする、アダパレンと過酸化ベンゾイルとの組合せを含む皮膚科学的組成物
JP2013527161A (ja) 2010-04-29 2013-06-27 ガルデルマ・リサーチ・アンド・デヴェロップメント アダパレン０．３％による瘢痕の処置方法
EP2854791A1 (en) 2012-05-25 2015-04-08 Galderma Research & Development Treatment of preadolescent moderate acne vulgaris
EP3220903A1 (fr) * 2014-11-20 2017-09-27 Galderma S.A. Compositions comprenant un compose de la famille des avermectines et un compose agoniste d'au moins un des recepteurs de l'acide retinoique pour le traitement de l'acne
KR102486502B1 (ko) * 2015-09-15 2023-01-09 주식회사 엘지생활건강 여드름 치료제 전달을 위한 용해성 미세바늘 패치

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU85849A1 (fr) * 1985-04-11 1986-11-05 Cird Derives benzonaphtaleniques,leur procede de preparation et leur application dans les domaines pharmaceutiques et cosmetiques
FR2730930B1 (fr) * 1995-02-27 1997-04-04 Oreal Utilisation d'inhibiteurs de no-synthase pour diminuer l'effet irritant cutane de produits utilises dans le domaine cosmetique ou pharmaceutique

Also Published As

Publication number Publication date
ZA200405853B (en) 2008-10-29
FR2837101A1 (fr) 2003-09-19
KR20040111394A (ko) 2004-12-31
FR2837101B1 (fr) 2004-07-02
KR101007161B1 (ko) 2011-01-12

Similar Documents

Publication Publication Date Title
ES2524320T3 (es) Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo
RU2008118056A (ru) Применение 6-[3-(1-адамантил)-4-метоксифенил]-2-нафтойной кислоты для лечения дерматологических расстройств
CO6150136A2 (es) Combinacion de adapaleno y peroxido de benzoilo para tratar lesiones de acne
AR038924A1 (es) Utilizacion del acido 6-[3-(1-adamantil)-4-metoxifenil)-2-naftoico para el tratamiento de desordenes dermatologicos
AR084691A1 (es) Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel
GT200600096A (es) Composicion farmaceutica para el tratamiento del cancer
ES2523018T3 (es) Ácidos grasos de cadena media aplicables como agentes anti-microbianos
NZ600167A (en) Concentrated therapeutic phospholipid compositions
BR112014031837A2 (pt) formulações de progesterona
AR065704A1 (es) Composiciones y equipos para el tratamiento de la influenza
RU2007101519A (ru) Композиция в форме спрея, содержащая в масляной фазе сочетание кортикоида и производного витамина d
AR064659A1 (es) Nanoemulsion
CO6300930A2 (es) Formulaciones orales de analogos de citidina y metodos para usar los mismos
CL2011003094A1 (es) Composicion farmaceutica semi-solida libre de agua que comprende a) un ester del acido 5-aminolevulinico (5-ala) o una sal del mismo, b) uno o mas trigliceridos y c) opcionalmente uno o mas potenciadores de viscosidad; kit farmaceutico; y su uso en el tratamiento fotodinamico del cancer, condiciones pre-cancerosas y no cancerosas asociadas a hpv.
CR9626A (es) Formas de dosificacion de liberacion retardada oral altamente biodisponible de un o-desmetilvenlafaxin succinato
CO6300927A2 (es) Sales de arginina y un cation, productos de cuidado oral y personal que los contienen y metodos para preparar dichas sales y productos
AR045504A1 (es) Composicion de ester ramificado
HN2008001771A (es) Esteres de dha
Saurat et al. Retinoids
US20140031427A1 (en) Combinations of adapalene and benzoyl peroxide for treating acne lesions
AR084197A1 (es) Composicion para uso topico para el tratamiento de trastornos de la piel
AR055629A1 (es) Formulaciones topicas con contenido de o- desmetilvenlafaxina (odv) o sus sales
NZ601001A (en) Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue
CY1117801T1 (el) Μασκα απολεπισης προσωπου απο πολυβινυλιο για τη θεραπευτικη αντιμετωπιση δερματικων παθησεων η οποια περιλαμβανει υψηλη συγκεντρωση ρητινοϊκου οξεος
AR056018A1 (es) Una composicion para usar en la piel

Legal Events

Date Code Title Description
FC Refusal